CEO Sharer defends Amgen amid anemia drug woes

09/10/2007 | Forbes

A day before an FDA panel reviews safety issues surrounding Aranesp and Epogen, Amgen chief executive Kevin Sharer assured investors that the company will be able to overcome current difficulties involving its anemia drugs. The Senate's request for the CMS to review its decision to restrict the treatments suggests public policy issues are at stake in the issue, Sharer said.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX